Journal article
EXTH-81. ITGA5 IS A NOVEL IMMUNOTHERAPEUTIC TARGET AGAINST TREATMENT REFRACTORY MEDULLOBLASTOMA
Abstract
Abstract
Medulloblastoma (MB) is the most common type of malignant pediatric brain cancer. Current standard of care (SOC) involves maximal safe resection and neuraxis radiotherapy and chemotherapy in individuals older than 3 years. To date, these cytotoxic SOC combined with craniospinal irradiation led to devastating neurocognitive and developmental deficits impacting quality of life for pediatric patients. The biological …
Authors
Bakhshinyan D; Suk Y; Kuhlman L; Adile A; Ignatchenko V; Gwynne W; Custers S; Macklin A; Venugopal C; Kislinger T
Journal
Neuro-Oncology, Vol. 24, No. Supplement_7, pp. vii228–vii228
Publisher
Oxford University Press (OUP)
Publication Date
November 14, 2022
DOI
10.1093/neuonc/noac209.879
ISSN
1522-8517